Australia’s CannPal Animal Therapeutics Limited (ASX:CP1) has announced it has commenced its Phase 2A pilot dose determination study for its canine osteoarthritis treatment, CPAT-01, and is looking for dogs to participate.
CannPal hopes CPAT-01 will prove to be an effective alternative to Non-Steroidal Anti-Inflammatory (NSAID) drugs.
Arthritis in dogs is very common, with an estimated 60% of dogs between the ages of 7 and 11 years experiencing the condition. As in humans, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may be prescribed, which can have side-effects including nausea, appetite loss and internal bleeding.
The clinical trial is an 8 week randomised, double-blind, placebo-controlled study with an estimated 60 dogs expected to participate. A dozen veterinary clinics across New South Wales and Queensland (6 in each state) have been enrolled for the study.
Recruitment of dogs has commenced and the first assessments are already occurring in New South Wales. The company is actively looking for candidates and says dogs older than 6 months and weighing more than 10 kilograms displaying signs of osteoarthritis such as limping, trouble getting up and hesitancy to negotiate stairs may be eligible for the study. Further details can be found here.
In other news from the company, the company said during the June quarter it completed analysis of additional blood samples taken from the Phase 1B dose ranging and pharmacokinetic study for CPAT-01, which provided insights into the dose response of cannabinoids in dogs ahead of the Phase 2 trials.
Dermacann Trial Starts Soon
CannPal also announced the company is in the closing preparatory stages for a field safety and efficacy study for DermaCann, which is an oral liquid nutraceutical product being developed to target skin health issues in dogs. 30 dogs experiencing symptoms associated with atopic dermatitis and/or allergic dermatitis are expected to be recruited for the trial, with recruitment to start this month.
Currently, there are no prescription animal medicines legally available for sale in the Asia-Pacific market containing cannabidiol (CBD), something that CannPal is attempting to address.
“Both of these trials are globally significant milestones, as they represent regulatory progress that is yet to be matched by an animal health company developing cannabinoid-derived products for pets,” said CannPal Founder and Managing Director, Layton Mills.
More from CannPal’s 4C Quarterly Cash Flow Report for June 2019 Quarter can be viewed here.